Bio News
Expedition Therapeutics has secured $115 million in a Series B financing round, equivalent to approximately 163.5 billion won. The company will use the funds to conduct a phase 2 clinical trial of EXPD-101, an investigational drug for chronic obstructive pulmonary disease (COPD). Expedition plans to advance the global clinical development of the DPP1 inhibitor, which it licensed from Fosun Pharma for $17 million, equivalent to approximately 24.2 billion won.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
